Breast Cancer Treatment Guidelines
The faculty in the Breast Oncology Program at Dana-Farber Brigham Cancer Center have developed guidelines on how to best utilize certain treatments recently approved by the Food and Drug Administration (FDA). The guidelines were drafted using data from available clinical trials and presented for feedback and expert consensus to a diverse group of Dana-Farber Brigham physicians, nurses, clinical investigators, lab investigators, translational researchers, administrators, and patient advocates. We are pleased to share our recommended guidelines which may be a helpful reference when using these new agents. In our discussions, we considered:
- Which patients should receive the treatment
- How the medication should be administered
- How the toxicities of the medication should be managed
The reports include reviews of the clinical trials that led to FDA approval as well as the above-mentioned recommendations for patient selection and treatment.
Trastuzumab Deruxtecan (T-DXd) for Metastatic, HER2-Low and HER2-Ultralow Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of trastuzumab deruxtecan (T-DXd) for patients with metastatic, HER2-low and HER2-ultralow breast cancer.
Adjuvant Ribociclib for Early-Stage Hormone Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of adjuvant ribociclib in patients with early-stage hormone receptor-positive breast cancer.
Adjuvant Abemaciclib for Early-Stage, Hormone-Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of adjuvant abemaciclib in patients with early-stage, hormone-receptor-positive breast cancer.
Patients With a History of Breast Cancer who Desire Pregnancy
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations for patients with a history of breast cancer who desire pregnancy.
Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on April 5, 2023 to discuss recommendations for the for the use of sacituzumab govitecan in patients with metastatic, HR-positive, HER2-negative breast cancer.
Elacestrant for Advanced Estrogen Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on February 24 and May 5, 2023 to discuss recommendations for the use of elacestrant in patients with advanced estrogen receptor-positive breast cancer.
Additional guidelines will be published here as new agents are approved by the FDA.